

Mortality (Longevity): Contributing Factors in the Past and for Projections, and Implications for the Future



**Steve Goss, Chief Actuary
US Social Security Administration**

**Expert Forum on Demographic Transitions: Impact on Longevity, Health and Economy
in collaboration with the Global Longevity Council of the World Demographic & Ageing Forum**

January 27, 2023

Employment Over Age 65...

declined briefly with the 2020 recession, but is projected to continue rising. How much of this is from changing the NRA and earnings test? *Is the best retirement approach a job (Paul Samuelson)?*



Outline

- First, current effects from COVID-19: future implications
- Level of mortality depends on exposed population and data source
- Approaches for projecting mortality
 - Extrapolation of past trends?
 - Or developing assumptions by cause of death—consulting experts
- Future conditions
 - Unlikely to replicate remarkable progress of the 20th century
 - Obesity
 - Health spending and climate change
 - Human limits
- Noting recent deceleration—what we expect
- Implications of shifting age distribution

COVID-19; Pandemics


- COVID-19 swept across the globe and continues
 - Enhanced population mobility
 - Highly evolving virus
- Remarkable new mRNA vaccine; recent bivalent booster
 - But only about 16% of eligible in US have taken it
- New variants are arriving regularly; mitigations have waned
- Now endemic?
- Will post-COVID conditions constrain longevity in the future?

In the US, BQ Overtook BA in November; XBB Now Matches BQ, and Dominates in NY/NJ

United States: 1/8/2023 – 1/14/2023 NOWCAST

WHO label	Lineage #	US Class	%Total	95%PI
Omicron	XBB.1.5	VOC	43.0%	26.4-61.1%
	BQ.1.1	VOC	28.8%	20.5-38.7%
	BQ.1	VOC	15.9%	11.0-22.2%
	XBB	VOC	3.9%	3.0-5.1%
	BA.5	VOC	2.6%	1.8-3.7%
	BN.1	VOC	2.1%	1.5-3.1%
	BF.7	VOC	1.4%	0.9-2.1%
	BA.2.75	VOC	1.3%	0.8-1.9%
	BA.5.2.6	VOC	0.5%	0.3-0.8%
	BA.2	VOC	0.2%	0.1-0.4%
	BF.11	VOC	0.2%	0.1-0.3%
	BA.4.6	VOC	0.1%	0.1-0.2%
	BA.2.75.2	VOC	0.1%	0.0-0.1%
	BA.1.1	VOC	0.0%	0.0-0.0%
	BA.4	VOC	0.0%	0.0-0.0%
	B.1.1.529	VOC	0.0%	0.0-0.0%
	BA.2.12.1	VOC	0.0%	0.0-0.0%
	Delta	B.1.617.2	VBM	0.0%
Other	Other*		0.0%	0.0-0.0%

United States: 10/9/2022 – 1/14/2023




* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.
 ** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
 # BA.1, BA.3 and their sublineages (except BA.1.1 and its sublineages) are aggregated with B.1.1.529. Except BA.2.12.1, BA.2.75, BA.2.75.2, BN.1, XBB and their sublineages, BA.2 sublineages are aggregated with BA.2. Except BA.4.6, sublineages of BA.4 are aggregated to BA.4. Except BF.7, BF.11, BA.5.2.6, BQ.1 and BQ.1.1, sublineages of BA.5 are aggregated to BA.5. Except XBB.1.5, sublineages of XBB are aggregated to XBB. For all the lineages listed in the above table, their sublineages are aggregated to the listed parental lineages respectively. Previously, XBB.1.5 was aggregated to XBB. Lineages BA.2.75.2, XBB, XBB.1.5, BN.1, BA.4.6, BF.7, BF.11, BA.5.2.6 and BQ.1.1 contain the spike substitution R346T.

HHS Region 2: 1/8/2023 – 1/14/2023 NOWCAST

WHO label	Lineage #	US Class	%Total	95%PI
Omicron	XBB.1.5	VOC	82.7%	75.5-88.2%
	BQ.1.1	VOC	8.4%	5.6-12.5%
	BQ.1	VOC	4.8%	2.7-8.3%
	XBB	VOC	2.3%	1.7-3.1%
	BA.5	VOC	0.8%	0.6-1.0%
	BN.1	VOC	0.3%	0.1-0.7%
	BF.7	VOC	0.2%	0.1-0.5%
	BA.2.75	VOC	0.2%	0.2-0.3%
	BA.5.2.6	VOC	0.1%	0.0-0.2%
	BF.11	VOC	0.0%	0.0-0.1%
	BA.2	VOC	0.0%	0.0-0.0%
	BA.4.6	VOC	0.0%	0.0-0.0%
	BA.2.75.2	VOC	0.0%	0.0-0.0%
	BA.1.1	VOC	0.0%	0.0-0.0%
	BA.4	VOC	0.0%	0.0-0.0%
	B.1.1.529	VOC	0.0%	0.0-0.0%
	BA.2.12.1	VOC	0.0%	0.0-0.0%
	Delta	B.1.617.2	VBM	0.0%
Other	Other*		0.0%	0.0-0.0%


HHS Region 2: 10/9/2022 – 1/14/2023




* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.
 ** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
 # BA.1, BA.3 and their sublineages (except BA.1.1 and its sublineages) are aggregated with B.1.1.529. Except BA.2.12.1, BA.2.75, BA.2.75.2, BN.1, XBB and their sublineages, BA.2 sublineages are aggregated with BA.2. Except BA.4.6, sublineages of BA.4 are aggregated to BA.4. Except BF.7, BF.11, BA.5.2.6, BQ.1 and BQ.1.1, sublineages of BA.5 are aggregated to BA.5. Except XBB.1.5, sublineages of XBB are aggregated to XBB. For all the lineages listed in the above table, their sublineages are aggregated to the listed parental lineages respectively. Previously, XBB.1.5 was aggregated to XBB. Lineages BA.2.75.2, XBB, XBB.1.5, BN.1, BA.4.6, BF.7, BF.11, BA.5.2.6 and BQ.1.1 contain the spike substitution R346T.

Across Europe and the Americas— The Fall/Winter Wave Rising in December

Reported Cases Rising




Reported Deaths Increasing in the New Year





Rise in Hospitalizations in January Makes Clear that New Cases are Increasingly Underreported

Weekly Trends in Number of Cases and Number of New Patients Admitted to Hospital with Confirmed COVID-19 per Week in The United States Reported to CDC



Cases and Deaths are Lower for Those Vaccinated, But How Much Due to Care and Greater Mitigation?



People aged 12 and older vaccinated with an updated (bivalent) booster had:

18.6X
lower risk of dying from COVID-19

in October 2022, and

3.1X
lower risk of testing positive for COVID-19

in November 2022, compared to unvaccinated people.

People aged 12 and older vaccinated with an updated (bivalent) booster had:



18.6X
lower risk of dying from COVID-19

in October 2022, and


3.1X
lower risk of testing positive for COVID-19

in November 2022, compared to unvaccinated people.


Relative Changes in Death Rates by Age, Total and PIC, Varied by Strain; Did Delta Reflect Earlier Vaccination for 65+?



Note the Lag in Reporting of Deaths in the US; Estimated Excess Deaths Rising in Late November



But Excess Deaths Are Not All From COVID; Currently May Be Largely From Other-Than-PIC



For Latest Complete Provisional Quarter, Age-Sex-Adjusted Death Rates Are All Elevated Over 2019

NCHS Provisional	Age-Adjusted Death Rates	2019Q3	2021Q3	Ratio 2021Q3/2019Q3
Alzheimer disease		27.6	29.7	1.08
COVID-19		#N/A	115.6	#N/A
Cancer		145.4	148.5	1.02
Chronic liver disease and cirrhosis		11.1	14.6	1.32
Chronic lower respiratory diseases		33.6	34.6	1.03
Diabetes		19.8	24.8	1.25
Drug overdose		22.4	33.5	1.50
Falls, ages 65 and over		64.2	75.7	1.18
Firearm-related injury		12.4	15.5	1.25
Heart disease		150.5	169.7	1.13
HIV disease		1.3	1.3	1.00
Homicide		6.4	8.7	1.36
Hypertension		8.2	10.3	1.26
Influenza and pneumonia		8.9	10.1	1.13
Kidney disease		11.7	13.1	1.12
Parkinson disease		8.3	9.6	1.16
Pneumonitis due to solids and liquids		4.1	4.9	1.20
Septicemia		8.7	10.2	1.17
Stroke		34.8	39.8	1.14
Suicide		14.7	14.7	1.00
<u>Unintentional injuries</u>		<u>51.3</u>	<u>67.6</u>	<u>1.32</u>
Total		645.4	852.5	1.32
Total w/o COVID		645.4	736.9	1.14

Now, Considerations in Projecting Mortality



- Frequency of future pandemics?
- Variation by age and over time periods
- Variation by earnings level
- Changing causes of death
- Cohort considerations
- Health spending, obesity, smoking, opioids
- Our projections for the United States
- Is there a limit on human longevity?

Pandemics in the Future

- Over the last 100 years, mortality has been about cause reduction
- But if pandemics raise deaths 15% for 2 years in every 20 years
 - Then the level of mortality would be raised by 1.5% per year on average
- But how about residual compromising effects—post-COVID?
 - How much will viability be diminished for the survivors?
- Earlier death later in life might be the larger factor
 - As with other compromising factors like smoking

Variation by Age Has Been Substantial


Reduction in mortality at higher ages is inherently more difficult




Mortality Decline Has *Varied* Over Time

Conditions: Antibiotics/economy 1936-54; Medicare/Medicaid 1968-82

Female Historical (2022 Trustees Report)
Annual Percent Reduction in U.S. Mortality Rates




Male Historical (2022 Trustees Report)
Annual Percent Reduction in U.S. Mortality Rates




US Mortality Experience: All Ages

Reductions falling short of expectations since 2009




US is Not Alone—United Kingdom Deceleration Since 2011

January 2023 Living to 100 Conference: Adrian Gallop, UK Government Actuary's Office




US Mortality Experience: Ages 65 and Over

Reductions falling short of expectations since 2009



US Mortality Experience: Under Age 65



Experience far worse than expectations since 2009



Mortality By Career-Average Earnings Level: Actuarial Study 124


So, crucial to scale to exposed population, but rate of change may be similar

Age group 65-69 relative mortality ratios—not diverging?




US Mortality Decline by *Cause of Death*:

Annual rate of decline from 1979 to 2019; note dementia vs. cardio over 50



Age-Adjusted Death Rates for Heart Disease, Cancer, Stroke, and Unintentional Injuries: United States, 1900-2021


(courtesy Robert Anderson, NCHS)



Notes: Data are from the National Vital Statistics System. Prior to 1933, data are for death-registration States only. Data for 2021 are provisional.


Age-Adjusted Death Rates for Heart Disease, Cancer, Stroke, and Unintentional Injuries: United States, 2000-2021

(courtesy Robert Anderson, NCHS)



Age-Adjusted Death Rates for Selected Causes: United States, 2000-2021

(courtesy Robert Anderson, NCHS)



Developing Assumptions by Cause

- Scientific approach reflecting biology and epidemiology
- Trustees and SSA/OCACT develop in consultation with other experts
- Centers for Disease Control/National Institutes of Health
- Johns Hopkins survey of medical researchers and clinicians

Cohort Considerations


- Post-World War 2 births—special conditions:
 - Antibiotics when young; statins, etc. later
- What does change up to age x say above age x ?
 - If cohort is fundamentally healthier at x :
Then expect lower mortality over age x
 - But if medical interventions have just reduced deaths:
Then cohort mortality over age x could be worse, with increased numbers of impaired survivors
 - What does one cohort imply for the next cohort?
Further changes depend on conditions, not trend

How Future Conditions Might Change

- Smoking decline for women
 - Started and stopped later than men
- Obesity—sedentary lifestyle
- Health spending—must decelerate
 - An ageing population, and Climate Change will strain resources
 - Advances help only if they apply to all
- Human limits
 - Increasing understanding of deceleration


Trends in Obesity: US 1971-2006

Sam Preston 2010—must consider *cumulative* effects; increasing duration of obesity for aged in future




Health Spending Cannot Continue to Rise at Historical Rates

Note Trustees' projected deceleration




Costs from Climate Change and the Increasing Share of the Adult Population over Age 65 will Strain Resources


Aging (change in age distribution) mainly due to drop in birth rates



Excluding immigration as well as fertility effects:



Our Ultimate (2046 to 2096) Projected Rates of Decline: Similar to Period Since 1900 for Ages 50+





	1900 to <u>2019</u>	2009 to <u>2019</u>	Projected 2046 to <u>2096</u>
Under Age 15	2.97	1.46	1.52
Ages 15 - 49	1.43	-0.55	0.85
Ages 50 - 64	0.99	0.03	0.96
Ages 65 - 74	0.91	0.92	0.71
<u>Ages 85 +</u>	<u>0.58</u>	<u>0.24</u>	<u>0.55</u>
Total	1.02	0.43	0.72

Assumed Ultimate Rates of Change by Age and Cause of Death



	Historical		Alternative II*		Historical		Alternative II*	
	1979 to 2019	2009 to 2019	2021 TR	2022 TR	1979 to 2019	2009 to 2019	2021 TR	2022 TR
	2045 to 2095	2046 to 2096	2045 to 2095	2046 to 2096	2045 to 2095	2046 to 2096	2045 to 2095	2046 to 2096
Under Age 15	Male				Female			
Cardiovascular Disease	1.94	2.22	1.9	1.9	1.68	1.62	1.9	1.9
Cancer	2.35	1.69	1.5	1.5	1.98	1.51	1.5	1.5
Violence and Accidents	2.38	0.25	1.0	1.0	2.07	-0.09	1.0	1.0
Respiratory Disease	2.27	2.04	2.0	2.0	2.45	2.63	2.0	2.0
Dementia	3.07	3.93	0.1	0.1	1.80	-1.78	0.1	0.1
Other	2.24	1.75	1.7	1.7	2.13	1.67	1.7	1.7
Resulting Total **	2.27	1.49	1.51	1.51	2.11	1.42	1.54	1.54
Ages 15 - 49	Male				Female			
Cardiovascular Disease	1.78	0.75	1.3	1.3	1.19	0.42	1.3	1.3
Cancer	1.88	2.26	1.5	1.5	1.58	1.77	1.5	1.5
Violence and Accidents	0.28	-2.44	0.7	0.7	-0.21	-2.35	0.7	0.7
Respiratory Disease	0.45	1.92	0.5	0.5	-0.47	2.08	0.5	0.5
Dementia	1.06	0.50	0.1	0.1	0.96	1.84	0.1	0.1
Other	0.14	0.32	0.8	0.8	-0.09	-0.06	0.8	0.8
Resulting Total **	0.72	-0.74	0.82	0.82	0.49	-0.21	0.89	0.89
Ages 50 - 64	Male				Female			
Cardiovascular Disease	2.36	0.19	1.5	1.5	1.96	0.06	1.5	1.5
Cancer	1.55	2.04	1.5	1.5	1.22	1.39	1.5	1.5
Violence and Accidents	-0.39	-3.34	0.5	0.5	-0.68	-2.73	0.5	0.5
Respiratory Disease	0.45	-0.33	0.7	0.7	-1.17	-0.75	0.7	0.7
Dementia	-2.51	-2.80	0.1	0.1	-3.23	-3.53	0.1	0.1
Other	-0.34	-0.66	0.6	0.6	-0.31	-0.84	0.6	0.6
Resulting Total **	1.23	0.03	0.95	0.95	0.82	0.02	0.98	0.98
Ages 65 - 84	Male				Female			
Cardiovascular Disease	2.73	1.31	1.9	1.9	2.61	1.69	1.9	1.9
Cancer	1.07	2.18	0.9	0.9	0.35	1.84	0.9	0.9
Violence and Accidents	0.25	-1.78	0.5	0.5	-0.13	-1.58	0.5	0.5
Respiratory Disease	0.48	1.50	0.3	0.3	-1.83	1.07	0.3	0.3
Dementia	-6.65	-1.89	0.1	0.1	-7.73	-2.39	0.1	0.1
Other	-0.29	-0.63	0.3	0.3	-0.44	0.15	0.3	0.3
Resulting Total **	1.36	0.92	0.74	0.74	0.80	0.93	0.68	0.68
Ages 85 and older	Male				Female			
Cardiovascular Disease	1.67	1.01	1.5	1.5	1.87	1.24	1.5	1.5
Cancer	0.00	0.83	0.5	0.5	-0.29	0.13	0.5	0.5
Violence and Accidents	-0.83	-1.80	0.3	0.3	-1.18	-2.16	0.3	0.3
Respiratory Disease	-0.45	1.59	0.2	0.2	-1.58	0.51	0.2	0.2
Dementia	-9.48	-2.15	0.1	0.1	-10.32	-2.36	0.1	0.1
Other	-0.83	0.06	0.3	0.3	-0.78	0.75	0.3	0.3
Resulting Total **	0.35	0.38	0.58	0.58	0.23	0.16	0.54	0.54
Total	Male				Female			
Cardiovascular Disease	2.27	0.99			2.18	1.26		
Cancer	1.04	1.87			0.62	1.44		
Violence and Accidents	0.12	-2.40			-0.27	-2.16		
Respiratory Disease	0.20	1.33			-1.54	0.69		
Dementia	-7.71	-2.06			-8.77	-2.38		
Other	-0.20	-0.26			-0.25	0.19		
Resulting Total **	1.02	0.45	0.74	0.74	0.62	0.45	0.69	0.69

Projected US Age-Sex-Adjusted Death Rates: Only Modest Deceleration *(note importance of log scale)*





Is There an Omega?

We have been rectangularizing the survival curve; few have actually lived beyond 100



More Important for Most Annuities is Survival after 65


Are we being overly optimistic in the percent who will survive from 65 to over 100?



Death Rates Will Continue to Decline: But How Fast and for Whom?

- Must understand past and future conditions
 - Persistent historical “age gradient”, lower improvement at high ages
 - Avoid simple extrapolation of past periods
 - » Cannot ignore changing conditions
 - “Limits” on longevity due to physiology
 - Latter half of 20th century was extraordinary
 - » So deceleration seems likely
 - » Cause-specific rates allow scientific basis for assumptions
 - Results: in the 1982 TR, we projected LE65 for 2015 to be 19.1; actual turned out to be 19.1

Ultimately, the Changing Age Distribution of the Population is the Main Factor for Financing Social Security and Retirement in General



Whether your retirement is financed through “advance funding” or “pay-as-you go financing,” it will be the current working population that will both:

- (1) produce the goods and services needed for all, and
- (2) maintain the value of investments held by all for their own current or future retirement.

For More Information...

<http://www.ssa.gov/oact/>

- Documentation of Trustees Report data & assumptions
https://www.ssa.gov/oact/TR/2022/2022_Long-Range_Demographic_Assumptions.pdf
- 2022 SOA ImpACT Conference, panel 13A with leading demographers
https://www.ssa.gov/oact/presentations/scgoss_20221027.pdf
- Historical and projected mortality rates
<https://www.ssa.gov/oact/HistEst/DeathHome.html>
- Annual Trustees Reports
<https://www.ssa.gov/oact/TR/index.html>